Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Fineline Cube Jan 20, 2026
Company Deals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

Fineline Cube Jan 20, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

Fineline Cube Jan 20, 2026
Company Drug

AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly

Fineline Cube Jan 20, 2026
Company Deals R&D

Tigermed Partners with Purpose Africa to Boost Clinical Research and Healthcare Cooperation

Fineline Cube Sep 9, 2024

Tigermed (SHE: 300347), a leading Contract Research Organization (CRO) in China, has entered into a...

Policy / Regulatory

China’s 2024 Negative List Eases Restrictions on Foreign Investment in TCM and Biotechnology

Fineline Cube Sep 9, 2024

The National Development and Reform Commission (NDRC) of China has announced the release of the...

Policy / Regulatory

China’s NMPA Proposes Inclusion of Cochlear Implants in Volume-Based Procurement Plans

Fineline Cube Sep 9, 2024

The National Medical Products Administration (NMPA) has disclosed plans to expand the scope of its...

Company Deals Medical Device

Edwards Lifesciences Sells ICU Business to BD in $4.2 Billion Deal, Announces Layoffs

Fineline Cube Sep 9, 2024

Edwards Lifesciences, a leading U.S. medical device company, has reportedly reached an agreement to sell...

Company Drug

Zelgen Biopharma’s ZG006 Shows Promising Anti-Tumor Efficacy in Phase I/II SCLC Study

Fineline Cube Sep 9, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Policy / Regulatory

China’s NHSA Proposes New Guidelines to Enhance Oversight of Medical Insurance Funds

Fineline Cube Sep 9, 2024

The National Healthcare Security Administration (NHSA) has unveiled a draft of the “Guiding Opinions on...

Company Deals

Caprico Biotechnologies and Mindray Medical Form Comprehensive Flow Testing Partnership

Fineline Cube Sep 9, 2024

Caprico Biotechnologies, Inc., a Chinese biotechnology company, has entered into a comprehensive partnership with Mindray...

Policy / Regulatory

China Opens Doors to Foreign Biotech and Wholly-Owned Hospitals in Healthcare Sector Expansion

Fineline Cube Sep 9, 2024

China’s Ministry of Commerce, National Health Commission, and National Medical Products Administration (NMPA) have jointly...

Company

Connect Biopharma Shifts Focus to US, Plans Further Reduction in China Workforce

Fineline Cube Sep 9, 2024

Connect Biopharma Holdings Ltd (NASDAQ: CNTB), a Sino-US biotechnology company that initially operated in Suzhou...

Policy / Regulatory

Guangzhou Health Commission Unveils Ten Measures to Boost Innovative Pharma and Medical Device Development

Fineline Cube Sep 9, 2024

On September 5, 2024, the Guangzhou Health Commission issued the “Guangzhou Health Commission’s Ten Measures...

Company Drug

Merck and Daiichi Sankyo’s Ifinatamab Deruxtecan Shows Promising Results in Phase II ES-SCLC Trial

Fineline Cube Sep 9, 2024

Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK), a leading U.S. pharmaceutical company, and its...

Company Policy / Regulatory

Biosecure Act Faces Opposition from Senior House Democrat Jim McGovern

Fineline Cube Sep 9, 2024

The trajectory of the US Biosecure Act through the House of Representatives encountered unexpected turbulence...

Company Drug Policy / Regulatory

China’s CDE Releases 86th Batch of Reference Preparations for Generic Drug Evaluation

Fineline Cube Sep 9, 2024

China’s Center for Drug Evaluation (CDE) has unveiled its 86th roster of reference preparations for...

Company Drug

Akeso’s Ivonescimab Shows Promising Results in Phase III Clinical Trial for Hepatocellular Carcinoma

Fineline Cube Sep 9, 2024

Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced that its first-in-class...

Company Legal / IP

AstraZeneca Faces Investigation in China Over Data Privacy and Unapproved Drugs

Fineline Cube Sep 6, 2024

AstraZeneca (NASDAQ: AZN), a leading UK pharmaceutical company, is reportedly under the spotlight in Shenzhen,...

Company Policy / Regulatory

U.S. House of Representatives to Review the Biosecure Act Amid Legislative Hurdles

Fineline Cube Sep 6, 2024

The U.S. House of Representatives is slated to take up the contentious Biosecure Act the...

Company Deals

Eli Lilly Partners with Genetic Leap for RNA-Targeted AI Drug Discovery

Fineline Cube Sep 6, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has...

Company

Euroapi to Downsize API Production, Citing Asian Competition and Market Stagnation

Fineline Cube Sep 6, 2024

Euroapi (EPA: EAPI), a French company and a spinoff from Sanofi established in 2022, has...

Company Deals

Rigel Pharmaceuticals Strikes Deal with Kissei for Development and Commercialization of Rezlidhia in East Asia

Fineline Cube Sep 6, 2024

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), a biopharmaceutical company based in the U.S., has entered into...

Company Drug

Sinocelltech’s Herpes Zoster Vaccine SCTV04C Clears NMPA for Clinical Trial

Fineline Cube Sep 6, 2024

Sinocelltech Group Ltd (SHA: 688520), a biopharmaceutical company based in China, has received approval from...

Posts pagination

1 … 246 247 248 … 611

Recent updates

  • Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal
  • Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study
  • AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly
  • Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus
  • Grand Pharmaceutical Files TLX591-CDx PSMA Diagnostic for Prostate Cancer in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Company Drug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

Company Drug

AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly

Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.